Study guide

3.2 Immunizations for Special Populations: Pregnancy, Asplenia, Immunocompromised, and Chronic Conditions

PTCB Immunization Administration Certificate Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacy Technician Scope of Practice, Regulations, and Immunization Basics

1.1 Scope of Practice, State Regulations, Protocols, and Collaborative Practice Agreements 1.2 Principles of Immunology: Antigens, Antibodies, Active vs. Passive Immunity, and Herd Immunity 1.3 Vaccine Types, Platforms, and Adjuvants

2 Chapter 2: Vaccine-Preventable Diseases and Clinical Pathophysiology

2.1 Respiratory Viral Pathogens: Influenza, COVID-19, and RSV 2.2 Bacterial Diseases: Pneumococcal, Meningococcal, Tetanus, Diphtheria, and Pertussis 2.3 Viral Hepatitis (Hep A & B), Polio, and Enteric/GI Infections 2.4 Childhood Exanthems and Oncogenic Viruses: MMR, Varicella, Zoster, and HPV

3 Chapter 3: ACIP Recommended Immunization Schedules and Special Populations

3.1 ACIP Routine Schedules, Catch-Up Principles, Minimum Intervals, and Spacing Rules 3.2 Immunizations for Special Populations: Pregnancy, Asplenia, Immunocompromised, and Chronic Conditions 3.3 Healthcare Personnel Requirements, Occupational Health, and Travel Vaccines

4 Chapter 4: Patient Assessment, Clinical Screening, and Contraindications

4.1 Patient Screening Protocols, Health History Questionnaires, and Immunization Information Systems (IIS) 4.2 Contraindications vs. Precautions: Absolute vs. Temporary Deferrals 4.3 Specific Allergen Screening: Egg, Gelatin, Latex, Yeast, Neomycin, and PEG/Polysorbate

5 Chapter 5: Vaccine Supplies, Reconstitution, and Aseptic Preparation

5.1 Aseptic Preparation, Visual Inspection, Beyond-Use Dating (BUD), and Single- vs. Multi-Dose Vials 5.2 Reconstitution Principles, Specific Diluents, and Incompatible Fluid Prevention 5.3 Syringe and Needle Selection: Gauges, Lengths, and Safety-Engineered Devices by Patient Profile

6 Chapter 6: Administration Routes, Anatomical Landmarks, and Injection Technique

6.1 Intramuscular (IM) Injection: Deltoid Landmark Anatomy, Needle Angle (90°), and Technique 6.2 Alternative IM Sites: Vastus Lateralis Landmark Anatomy in Infants and Adults 6.3 Subcutaneous (SC) Injection: Triceps / Thigh Anatomy, Needle Angle (45°), and Technique 6.4 Intranasal (LAIV), Oral (Rotavirus), and Alternative Route Administration Techniques

7 Chapter 7: Infection Control, Safety Devices, and Workplace Standards

7.1 Standard Precautions, Hand Hygiene, and Personal Protective Equipment (PPE) 7.2 OSHA Bloodborne Pathogens Standard, Needlestick Prevention, and Sharps Disposal 7.3 Pain Mitigation Strategies, Patient Positioning, and Pediatric Comfort Measures

8 Chapter 8: Vaccine Storage, Handling, and Cold Chain Integrity

8.1 CDC Cold Chain Requirements: Purpose-Built Units, Placement, and Temperature Ranges 8.2 Temperature Monitoring, Digital Data Loggers (DDLs), Buffered Probes, and Daily Logs 8.3 Temperature Excursions, Emergency Action Plans, Power Failures, and Transport Protocols

9 Chapter 9: Post-Vaccine Observation, Emergency Response, and Documentation

9.1 Post-Vaccination Observation Periods, Vasovagal Syncope Prevention, and Management 9.2 Acute Anaphylaxis Recognition, Emergency Protocols, and Intramuscular Epinephrine Dosing 9.3 Vaccine Information Statements (VIS) Statutory Mandates, Informed Consent, and Patient Communication 9.4 Clinical Documentation Standards, State IIS Reporting, VAERS, VERP, and VICP

3.2 Immunizations for Special Populations: Pregnancy, Asplenia, Immunocompromised, and Chronic Conditions

Key Takeaways Explain This Topic AI

In pregnancy, inactivated influenza or recombinant influenza is indicated in any trimester, Tdap is recommended during weeks 27–36 of EVERY pregnancy to optimize transplacental pertussis antibody transfer, and maternal RSV (Abrysvo) is indicated at 32–36 weeks gestation during seasonal windows.

MMR, varicella, LAIV, and live oral typhoid are contraindicated during pregnancy; yellow fever is a precaution that may be given when unavoidable exposure risk outweighs vaccine risk. Follow vaccine-specific conception guidance after live vaccination.

Patients with anatomic or functional asplenia (including sickle cell disease or post-splenectomy) have profound susceptibility to encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b) and require comprehensive immunization with PCV20 (or PCV15+PPSV23), MenACWY, MenB, and Hib.

Altered immunocompetence (due to HIV with CD4 < 200 cells/mm3, chemotherapy, solid organ transplant, TNF-alpha inhibitors, or high-dose corticosteroids >=20 mg/day prednisone equivalent for >=14 days) contraindicates live vaccines; however, recombinant zoster vaccine (Shingrix) is specifically indicated for immunocompromised adults age 19 and older.

Chronic medical conditions (diabetes mellitus, chronic heart/lung/liver/renal disease, alcoholism, and smoking) warrant targeted vaccination protocols, including universal hepatitis B for all adults with diabetes under age 60 (and clinical discretion for >=60) and risk-based pneumococcal and annual influenza coverage.

Last updated: August 2026

3.2 Immunizations for Special Populations: Pregnancy, Asplenia, Immunocompromised, and Chronic Conditions

Core Clinical Principle: High-risk patient populations exhibit altered immunological responses, heightened vulnerability to invasive encapsulated infections, or potential physiological risks to fetal development. Pharmacy technicians must strictly identify which vaccines are mandatory , which are contraindicated , and the exact timing thresholds that govern safe administration in maternal health, asplenia, immunosuppression, and chronic disease states.

1. Maternal Immunization: Pregnancy and Lactation

Maternal vaccination serves a dual purpose: protecting the pregnant individual against severe illness and mortality while facilitating active transplacental IgG transfer to protect the infant during the vulnerable first six months of life before pediatric vaccine series achieve protective titers. +---------------------------------------------------------------------------------------------------+

  • | MATERNAL IMMUNIZATION PROTOCOLS (PREGNANCY) |
  • | |
  • | VACCINE GESTATIONAL TIMING CLINICAL RATIONALE |
  • | ------------------ ----------------------------- ---------------------------------------- |
  • | Inactivated Flu Any Trimester (Seasonally) Prevents severe maternal cardiopulmonary |
  • | (IIV / RIV) complications and newborn influenza. |
  • | |
  • | Tdap 27 through 36 Weeks Gestation Optimizes transplacental transfer of |
  • | (EVERY single pregnancy) maternal anti-pertussis IgG antibodies. |
  • | |
  • | RSV (Abrysvo ONLY) 32 through 36 Weeks Gestation Protects infant against severe lower |
  • | (Sept–Jan in contiguous US) respiratory tract disease (LRTD). |
  • | |
  • | COVID-19 Any Trimester Prevents severe maternal ICU admission, |
  • | (Updated mRNA) stillbirth, and preterm delivery. |
  • +---------------------------------------------------------------------------------------------------+
  • Tdap in Pregnancy: The 27–36 Week Window

Recommended During Every Pregnancy: ACIP recommends administering one dose of Tdap during EACH pregnancy , regardless of the patient's prior history of receiving Td or Tdap.

Optimal Timing: Administered between 27 and 36 weeks gestation (preferably early in this window, around weeks 27–30). This allows 2 to 4 weeks for maternal B-cell antibody production and active neonatal Fc receptor-mediated transplacental IgG transport, resulting in high cord-blood pertussis antibody titers.

Postpartum Catch-Up: If a patient has never received Tdap and it was not administered during pregnancy, CDC recommends postpartum Tdap; a patient who previously received Tdap does not need an additional postpartum dose solely because the pregnancy window was missed.

Maternal RSV Vaccination (Abrysvo)

Approved Formulation: Only Pfizer's Abrysvo (unadjuvanted bivalent RSVpreF) is approved and recommended by ACIP for pregnant individuals. GSK's Arexvy and Moderna's mResvia are NOT approved in pregnancy.

Timing: Administer one dose at 32 0/7 through 36 6/7 weeks gestation from September through January across most of the continental United States. CDC does not currently recommend another maternal RSV vaccine dose in a subsequent pregnancy; the infant should receive recommended monoclonal antibody protection instead.

Alternative Strategy: If maternal Abrysvo is given >=14 days before delivery, the newborn generally does not need infant RSV antibody. If the mother is unvaccinated, maternal status is unknown, or delivery occurs <14 days after vaccination, an eligible infant younger than 8 months receives nirsevimab (Beyfortus) or clesrovimab (Enflonsia); only nirsevimab is recommended for eligible high-risk children entering a second RSV season.

Contraindicated Vaccines During Pregnancy

Live Vaccines: MMR, Varicella, Live Attenuated Influenza (LAIV), and Live Oral Typhoid (Ty21a) are contraindicated during pregnancy. Yellow fever is a precaution, not an absolute contraindication : if travel is unavoidable and exposure risk outweighs vaccination risk, it may be given after clinical assessment; otherwise defer travel or issue a waiver.

Conception Deferral: Women receiving live vaccines must be advised to avoid pregnancy for at least 28 days (4 weeks) after vaccination.

Accidental Administration: If a live vaccine is inadvertently given during pregnancy, the patient should be reassured that adverse fetal outcomes have not been documented, and pregnancy termination is NOT recommended.

Lactation Safety: Breastfeeding is not a contraindication to most vaccines, including MMR and varicella. Yellow fever vaccination is generally avoided while breastfeeding because rare infant meningoencephalitis has occurred; if travel cannot be avoided, the clinician weighs exposure risk and follows current CDC guidance.

2. Anatomic and Functional Asplenia

Patients with anatomic asplenia (surgical splenectomy, congenital asplenia) or functional asplenia (Sickle Cell Disease, hemoglobinopathies, severe celiac disease) lack splenic macrophage phagocytosis and IgM-secreting marginal zone B-cells. They face life-threatening susceptibility to encapsulated bacterial pathogens , leading to Overwhelming Post-Splenectomy Infection (OPSI) with rapid-onset septic shock and a mortality rate exceeding 50%. +---------------------------------------------------------------------------------------------------+

  • | VACCINE PROTOCOLS FOR ASPLENIA / SICKLE CELL DISEASE |
  • | |
  • | TARGET PATHOGEN RECOMMENDED VACCINE REGIMEN & SCHEDULE |
  • | ---------------------------- --------------------------------------------------------------- |
  • | Streptococcus pneumoniae - PCV20 (Single Dose), OR |
  • | (Pneumococcal) - PCV15 (1 Dose) followed by PPSV23 >=8 Weeks Later. |
  • | |
  • | Neisseria meningitidis - MenACWY (MenQuadfi / Menveo): 2-Dose Primary Series |
  • | (Meningococcal Serogroups (spaced >=8 weeks apart) + Booster Every 5 Years for life. |
  • | A, C, W, Y and B) - MenB (Bexsero or Trumenba 3-dose series at |
  • | 0, 1-2, 6 mo) + Booster at 1 Year and Every 2-3 Years. |
  • | |
  • | Haemophilus influenzae type b - Hib (ActHIB / Hiberix / PedvaxHIB): 1 Dose in adulthood |
  • | (Hib) if not previously vaccinated during childhood. |
  • +---------------------------------------------------------------------------------------------------+
  • Timing for Elective vs. Emergency Splenectomy

Elective Splenectomy (Planned Surgery): Administer all indicated vaccines (Pneumococcal, MenACWY, MenB, Hib) at least 14 days prior to surgery to maximize splenic antigen capture and antibody titer generation.

Emergency Splenectomy (Trauma): Defer vaccination until post-operative day 14 (or at hospital discharge) because immediate post-surgical immunologic paralysis blunts antibody seroconversion.

3. Altered Immunocompetence (Immunosuppression)

Immunocompromise arises from congenital immunodeficiencies, HIV infection, malignant neoplasms, solid organ or hematopoietic stem cell transplants, and immunosuppressive pharmacotherapy.

Defining Severe Immunosuppression Thresholds

High-Dose Systemic Corticosteroids: Defined by ACIP as receiving >=20 mg/day of prednisone (or >=2 mg/kg/day for children) for 14 or more consecutive days . Live vaccines are contraindicated during therapy and for at least 1 month (28 days) after cessation .

Non-Immunosuppressive Steroid Regimens: <20 mg/day prednisone, short courses (<14 days), alternate-day physiologic replacement, topical, inhaled, or intra-articular injections do NOT contraindicate live vaccines.

HIV Infection:

CD4 < 200 cells/mm3 (or CD4% < 15%): Severe immunosuppression. ALL live vaccines (MMR, Varicella, LAIV) are strictly CONTRAINDICATED .

CD4 >= 200 cells/mm3 (and CD4% >= 15%) for >=6 months: MMR (2 doses >=28 days apart) and Varicella (2 doses >=3 months apart) may be administered if non-immune.

Biologic DMARDs and Targeted Immunosuppressants: TNF-alpha inhibitors (infliximab, adalimumab, etanercept), anti-CD20 monoclonal antibodies (rituximab), IL-6 inhibitors, and JAK inhibitors contraindicate live vaccines. Inactivated vaccines should be given at least 2 weeks prior to initiating biologics.

Recombinant Zoster Vaccine (Shingrix) in Immunocompromised Adults

Indications: Shingrix is a non-live, recombinant glycoprotein E adjuvanted vaccine indicated for all immunocompromised adults aged 19 years and older (including patients with HIV, solid organ transplant, hematologic malignancy, and autoimmune diseases on immunosuppression).

Dosing Schedule: 2-dose series (0 and 2–6 months; can use an accelerated 0 and 1–2 month schedule if immunosuppression is imminent).

4. Chronic Medical Conditions

Medical Condition Key Pathophysiology & Vulnerability Indicated and Recommended Vaccines

Diabetes Mellitus (Type 1 & 2) Impaired neutrophil phagocytosis; risk of blood glucose monitor transmission. Hepatitis B (universal for age 19–59; clinical discretion for >=60), Pneumococcal (PCV20 or PCV15+PPSV23), Influenza (annual).

Chronic Lung Disease (COPD, Asthma) Bronchial epithelial damage; impaired ciliary clearance. Influenza (annual IIV/RIV; avoid LAIV in asthma/COPD), Pneumococcal (PCV20 or PCV15), RSV (age 50–74 with increased risk; all age 75+).

Chronic Renal Disease (ESRD / Hemodialysis) Uremic immunosuppression; hemodialysis vascular access hepatitis B transmission. High-Dose Hepatitis B (e.g., dialysis-dose Recombivax HB at 0, 1, and 6 months or Engerix-B at 0, 1, 2, and 6 months), Pneumococcal , Influenza .

Chronic Liver Disease (Cirrhosis, Hep C, NAFLD) Fulminant hepatic failure if superinfected with viral hepatitis. Hepatitis A (2 doses), Hepatitis B (2 or 3 doses), Pneumococcal , Influenza .

Cardiovascular Disease (Heart Failure, CAD) Acute infection triggers myocardial infarction and decompensation. Influenza (annual), Pneumococcal , COVID-19 , RSV (age 50–74 with increased risk; all age 75+).

Loading diagram... Special Populations Immunization and Safety Decision Pathways